medRxiv Preprint Server
May 5, 2026
Nicholas C. Borgogna, D. Drew Whittington, Tyler Owen et al.
preprint
Mental illness poses a substantial global burden, yet existing psychotherapies and psychopharmacologies often produce limited outcomes. Psychedelic-assisted therapies have re-emerged as potential transdiagnostic interventions. In particular, 3,4-methylenedioxymethamphetamine–assisted therapy (MDMA-AT) has generated interest for its rapid psychological effects and potential to enhance...
Current Treatment Options in Psychiatry
November 11, 2025
Dan Petrovitch, Sarah E. Victor, André Schmidt et al.
2 citations
Abstract Purpose of Review This commentary summarizes how the intense and distinctive subjective effects of psychedelics complicate tests of the efficacy and mechanisms of action (MOAs) of psychedelic-assisted treatments (PATs) for mental-health conditions. Specifically, we discuss (a) how estimates of PAT efficacy are confounded under functional unblinding and (b) uncertainty surrounding...
Psychopharmacology
April 23, 2025
Nicholas C. Borgogna, Tyler Owen, Dan Petrovitch et al.
8 citations
Abstract Rationale Psilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psilocybin-for-depression randomized controlled trials (RCTs). Objectives Systematically assess harm reporting, risk of bias, action mechanism specification, and incremental therapeutic effect sizes in the psilocybin-for-depression RCT literature....
Psychiatry Research Case Reports
March 24, 2025
Dan Petrovitch, Jacob Spinks, H.J. Yoo et al.
3 citations
Ketamine has demonstrated early promise for treating substance use disorder (SUD). Despite the emerging evidence for ketamine-based approaches for SUD, little has been published on the integration of ketamine-assisted psychotherapy (KAP) with existing pharmacologic, psychosocial, and peer-support approaches to treatment and recovery, including 12-step programs. Here, we present the case of a...
Drug Science Policy and Law
March 1, 2025
Dan Petrovitch, Jason van Allen, Sean M. Mitchell et al.
1 citation
Psychedelic drug policy is changing, both in the USA and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for safety, therapeutic efficacy, likely future legality, and more. We compared...
February 28, 2025
Dan Petrovitch, Samuel Hosford, Andrew K. Littlefield et al.
preprint
Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional psychotherapy. Despite limited formal regulatory approval, treatment seekers can currently access PAT through a variety of avenues, including ketamine treatment centers and “supported adult use” psilocybin centers in the U.S., drug tourism,...